InMed Pharmaceuticals
9 hedge funds and large institutions have $14.5K invested in InMed Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
2.56% less ownership
Funds ownership: 3.03% → 0.47% (-2.6%)
18% less funds holding
Funds holding: 11 → 9 (-2)
100% less capital inflows, than outflows
Capital inflows: $24 | Capital outflows: $93.1K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$24 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$84K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.22K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.83K |
| 4 |
Advisory Services Network
Atlanta,
Georgia
|
-$6 |
| 5 |
TCI Wealth Advisors
Tucson,
Arizona
|
-$6 |
INM Hedge Fund Activity: Q2 2023 in Review
9 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q2 2023, worth a combined $14.5K — down 87% from $109K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of INM and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Bank of America, adding an estimated $24. The largest seller was Renaissance Technologies, exiting entirely with an estimated $84K sold.
- 9 institutional investors held InMed Pharmaceuticals (INM) as of Q2 2023, down from 11 in Q1 2023.
- Funds reported $14.5K of InMed Pharmaceuticals stock for Q2 2023, down 87% quarter-over-quarter.
- 0 funds opened new InMed Pharmaceuticals positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest InMed Pharmaceuticals buyer in Q2 2023 was Bank of America, an estimated $24 added.
- The largest InMed Pharmaceuticals seller in Q2 2023 was Renaissance Technologies, an estimated $84K sold.
Based on aggregated 13F filings for Q2 2023.